Τόμος 32 (2018) – Τεύχος 3 –Άρθρο 3 – Review of Clinical Pharmacology and Pharmacokinetics – Διεθνής Έκδοση – Volume 32 (2018) – Issue 3 – Article 3 – Review of Clinical Pharmacology and Pharmacokinetics – International Edition

By | | Πλήρες Κείμενο στα Αγγλικά - Full Text in English
Τίτλος – Title
Age distribution of metabolic syndrome in Greek female with Polycystic Ovary Syndrome. A retrospective study
Συγγραφέας – Author
Giannoula Kyrkou1, Eftichios Trakakis2, Achilleas Attilakos1, Kleanthi Gourounti3, Aikaterini Lykeridou3

1Third Department of Pediatric, University of Athens “Attikon” Hospital, Athens, Greece

2Third Department of Obstetrics & Gynecological, University of Athens “Attikon” Hospital, Athens, Greece

3Midwifery Department, University of West Attica, Athens, Greece
Παραπομπή – Citation

G. Kyrkou, E. Trakakis, A. Attilakos, K. Gourounti, A. Lykeridou. Age distribution of metabolic syndrome in Greek female with Polycystic Ovary Syndrome. A retrospective study. Review Clin. Pharmacol. Pharmacokinet. 2018, 32, 3, 125-129
Ημερομηνία Δημοσιευσης – Publication Date
23-10-2018
Γλώσσα Πλήρους Κειμένου –
Full Text Language

Αγγλικά – English
Λέξεις κλειδιά – Keywords
Polycystic Ovary Syndrome, prevalence, Metabolic Syndrome
Λοιποί Όροι – Other Terms

Μελέτη Ανασκόπησης

Retrospective study
Περίληψη –Summary

Polycystic Ovary Syndrome (PCOS) is among the most common endocrine disorders of women in the reproductive age group. PCOS has been strongly associated with metabolic syndrome (MS) and insulin resistance, so there is an increased prevalence of MS in women with PCOS. Aim: Aim of this study was to investigate the age distribution of MS in Greek women with PCOS. Method and Material: 230 Greek women, who have been diagnosed with PCOS according to the criteria of ESHRE, aged from 12 to 44 years, were included in the study concerning the abdominal circumference, the fasting glucose, the TG plasma levels and the HDL plasma levels. Results: The prevalence of MS of Greek women with PCOS was 10% (International Diabetes Federation criteria)

Finally the diastolic blood pressure was in 6.1% higher than >85mm/Hg and the systolic blood pressure was in 4,3% higher than >130mm/Hg. The pathological variables The prevalence of MS according to age was as following: 12 to 19 years 0%, 20 to 24 years 6.75%, 25to 29 years 9.62%, 30to 34 years 17.14% and 35 to 44 years 55,56%. The pathological variables of MS in all age groups have the primary findings of increased abdominal circumference and secondary finding the decreased levels of HDL, also we observed a gradual increased in diastolic blood pressure and fasting glucose. Conclusion: PCOS remains one of the most common endocrine disorders of women in the reproductive age group. Most frequent the MS appears in ages from 35 to 44 while the rate decreases in younger women.
Αναφορές – References
  1. Stein I, Leventhal M. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29:181.
  2. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8:41. doi: 10.1186/1741-7015-8-41.
  3. Azziz R, Marin C, Hoq L, Badamgarav E, Song P. Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span. J Clin Endocrinol Metab. 2005;90:4650–8. doi: 10.1210/jc.2005-0628.
  4. Dokras A, Bochner M, Hollinrake E, Markham S, VanVoorhis B , Jagasia DH . Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol. 2005;106:131–7. doi: 10.1097/01.AOG.0000167408.30893.6b.
  5. Sam S, Legro RS, Bentley-Lewis R, Dunaif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:4797–802. doi: 10.1210/jc.2004-2217.
  6. Hudecova M, Holte J, Olovsson M, Larsson A, Berne C, Sundstrom-Poromaa I. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertil Steril. 2011;96:1271–4.

       doi: 10.1016/j.fertnstert.2011.08.006.

  1. Cheung LP, Ma RC, Lam PM, et al. (2008) Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 23:1431-143
  2. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA (2006) Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS Eur J Endocrinol 154:141-145
  3. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in with polycystic ovary syndrome. CLin Endocrinol Metab 2005; 90:1929-1935
  4. Carmina E, Legro RS, Stamets K, Lowell J, Lobo RA (2003) Difference in body weight between American and Italian women with polycystic ovary syndrome: influence of the diet. Hum Reprod 18:2289-2293
  5. Azizi F, Salehi P, Etemadi A, Zahedi-Asl S (2003) Prevalence of metabolic syndrome in an urban population: Tehran Lipid and Glucose Study. Diabetes Res Clin Pract 61:29-37
  6. Athyros VG, Bouloukos VI, Pehlivanidis AN, et al. (2005) MetS-Greece Collaborative Group. The prevalence of the metabolic syndrome in Greece: the MetS-Greece Multicentre Study. Diabetes Obes Metab 7:397-405
  7. Panagiotakos DB, Pitsavos C, Chrysohoou C, et al. (2004) Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 147:106-112
  8. Third Report of the National Cholesterol Education Program (NCEP) 2002 Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106:3143–3421
  9. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf, last accessed in August 2007
  10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. 112:2735-52.
  11. Carmina E, Napoli N, Longo R, Rini G, Lobo R. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141–5. doi: 10.1530/eje.1.02058. [PubMed][Cross Ref]
  12. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2005;90:1929–35. doi: 10.1210/jc.2004-1045. [PubMed][Cross Ref]
  13. Ranasinha S, Joham AE, Norman RJ, Shaw JE, Zoungas S, Boyle J. et al. The association between Polycystic Ovary Syndrome (PCOS) and metabolic syndrome: a statistical modelling approach. Clin Endocrinol. 2015;83:879–87. doi: 10.1111/cen.12830. [PubMed][Cross Ref]
  14. The IDF consensus worldwide definition of the metabolic syndrome in children and adolescents http://www.idf.org/webdata/docs/Mets_definition_children.pdf accessed in 2007
  15. Ferriman D, Gallwey JD (1961) Clinical assessment of body hairgrowth in women. J Clin Endocrinol Metab 21:1440–1447
  16. Kauffman, R.P., Baker, T.E., Baker, V.M., DiMarino, P., Castracane, V.D., 2008. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. American Journal of Obstetrics and Gynecology. 198, 670.e1–670.e10
  17. Goverde AJ, van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, Broekmans FJ Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod. 2009 Mar;24(3):710-7
  18. Marcondes JA, Hayashida SA, Barcellos CR, Rocha MP, Maciel GA, Baracat EC. Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors. Arq Bras Endocrinol Metabol. 2007 Aug;51(6):972-9.
  19. Bhattacharya SM (2008) Metabolic syndrome in females with polycystic ovary syndrome and International Diabetes Federation criteria. J Obstet Gynaecol Res34:62-66
  20. Cussons AJ, Watts GF, Burke V, Shaw JE, Zimmet PZ, Stuckey BG (2008) Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome. Hum Reprod 23:2352-2358
  21. Panidis D, Macut D, Tziomalos K, et al. (2013) Prevalence of metabolic syndrome in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 78:586-592
  22. Moini A, Javanmard F, Eslami B, Aletaha N. (2012) Prevalence of metabolic syndrome in polycystic ovarian syndrome women in a hospital of Tehran. Iran J Reprod Med. 10(2):127-30.
  23. Madani T, Hosseini R, Ramezanali F, Khalili G, Jahangiri N, Ahmadi J, et al. (2016) Metabolic syndrome in infertile women with polycystic ovarian syndrome. Archives of Endocrinology and Metabolism. 60:199-204.
Σχετικές Εργασίες – Relative Papers

Online ISSN 1011-6583

Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
• Chemical Abstracts

• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Articles published in this Journal are Indexed or Abstracted in:
• Chemical Abstracts
• Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE
SCImago Journal and Country Rank Factor

Τι είναι η Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση-Οδηγίες προς τους Συγγραφείς
What is Review of Clinical Pharmacology and Pharmacokinetics-International Edition-Instrunctions to Authors

Άρθρα Δημοσιευμένα στην Review of Clinical Pharmacology and Pharmacokinetics-Διεθνής Έκδοση
Articles Published in Review of Clinical Pharmacology and Pharmacokinetics-International Edition

Συντακτικη Επιτροπή-Editorial Board

Bookmark the permalink.

Comments are closed.